TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04430634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant B
Description: Use of Myblu e-cigarette with flavor B 3.6% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant C
Description: Use of Myblu e-cigarette with flavor C 2.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant C
Description: Use of Myblu e-cigarette with flavor C 2.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant C
Description: Use of Myblu e-cigarette with flavor C 2.5% nicotine
Study: NCT01753700

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: UHT treated milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UHT treated milk
Study: NCT04430634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant C
Description: Use of Myblu e-cigarette with flavor C 2.5% nicotine
Study: NCT01203722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytoxan
Description: Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytoxan
Description: Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytoxan
Description: Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytoxan
Description: Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day
Study: NCT04430634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant D
Description: Use of Myblu e-cigarette with flavor D 4.0% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant D
Description: Use of Myblu e-cigarette with flavor D 4.0% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant D
Description: Use of Myblu e-cigarette with flavor D 4.0% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant D
Description: Use of Myblu e-cigarette with flavor D 4.0% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant E
Description: Use of Myblu e-cigarette with flavor E 3.6% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant E
Description: Use of Myblu e-cigarette with flavor E 3.6% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant E
Description: Use of Myblu e-cigarette with flavor E 3.6% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant E
Description: Use of Myblu e-cigarette with flavor E 3.6% nicotine
Study: NCT01203722

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: 400 cGy TBI administered in a single fraction

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: 400 cGy TBI administered in a single fraction

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: 400 cGy TBI administered in a single fraction

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: 400 cGy TBI administered in a single fraction
Study: NCT04430634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant F
Description: Use of Myblu e-cigarette with flavor F 2.4% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant F
Description: Use of Myblu e-cigarette with flavor F 2.4% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant F
Description: Use of Myblu e-cigarette with flavor F 2.4% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant F
Description: Use of Myblu e-cigarette with flavor F 2.4% nicotine
Study: NCT01203722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Blood or Marrow Transplant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Blood or Marrow Transplant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Blood Stem Cell Transplant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Blood Stem Cell Transplant
Study: NCT04430634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant G
Description: Use of Myblu e-cigarette with flavor G 4.0% nicotine
Study: NCT02435667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Max Exercise Test
Description: Pedaling on a cycle ergometer to volitional fatigue.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cardiopulmonary Max Exercise Test
Description: Pedaling on a cycle ergometer to volitional fatigue.
Study: NCT04430634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant G
Description: Use of Myblu e-cigarette with flavor G 4.0% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant G
Description: Use of Myblu e-cigarette with flavor G 4.0% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant G
Description: Use of Myblu e-cigarette with flavor G 4.0% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant H
Description: Use of Myblu e-cigarette with flavor H 3.6% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant H
Description: Use of Myblu e-cigarette with flavor H 3.6% nicotine
Study: NCT02435667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaire
Description: A 10 minute questionnaire that measures quality of life.
Study: NCT02416024

Intervention type: DEVICE
Intervention: SphygmoCor system
Description: Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.

Intervention type: DEVICE
Intervention: SphygmoCor system
Description: Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
Study: NCT02435667

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life Questionnaire
Description: A 10 minute questionnaire that measures quality of life.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submaximal Exercise Test
Description: Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
Study: NCT04430634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant H
Description: Use of Myblu e-cigarette with flavor H 3.6% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant H
Description: Use of Myblu e-cigarette with flavor H 3.6% nicotine
Study: NCT01627652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: altitude
Description: the subjects will live one month at 3450 m altitude in the Jungfraujoch Research Station
Study: NCT04092205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emeramide
Description: Lipophilic, membrane passing Metal chelator and anti oxidant
Study: NCT00558506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: intravenously 750mg (in patients with weight of 60- 100kg)
Study: NCT02335554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoodHacker
Description: Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Care
Description: Online information about depression from government and other trusted sources to educate users about depression.
Study: NCT02435667

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Submaximal Exercise Test
Description: Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
Study: NCT02424201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: experimental

Intervention type: DRUG
Group type: OTHER
Intervention: vitamin c
Description: control
Study: NCT03169413

Intervention type: GENETIC
Intervention: Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.
Description: Gene study

Intervention type: GENETIC
Intervention: Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.
Description: Gene study

Intervention type: GENETIC
Intervention: Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.
Description: Gene study
Study: NCT01199133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dpte and Dfar Allergen Extracts
Description: 300 IR, once a day, for one year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once a day, for one year.
Study: NCT03695757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part A) Healthy subjects
Description: Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
Study: NCT00329472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, cisplatin
Study: NCT01120041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing counseling
Description: Motivational interviewing counseling given during the prenatal and postpartum phases

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing counseling
Description: Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing counseling
Description: Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: health education
Description: Traditional health education given during the prenatal phase and the postpartum phase
Study: NCT01203722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 15mg/kg by mouth three times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 15mg/kg by mouth three times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 15mg/kg by mouth three times daily
Study: NCT02435667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: A blood draw amounting to 1 teaspoon of blood drawn.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood Draw
Description: A blood draw amounting to 1 teaspoon of blood drawn.
Study: NCT01815424

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo BID for 16 weeks and then re-randomized into active groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 5mg BID for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 10mg BID for 52 weeks
Study: NCT05447390

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Handgrip strength test
Description: The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Handgrip strength test
Description: The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
Study: NCT01203722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 15mg/kg by mouth three times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily
Study: NCT03838614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT)
Description: The RAS-MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive two levels of training within each 60-minute session: (1) RAS-treadmill training and (2) MPT.
Study: NCT03695757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part B) Advanced solid tumor
Description: Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
Study: NCT00701701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme® (alglucosidase alfa)
Description: Myozyme®: IV infusion of 20 mg/kg qow; Cyclophosphamide: 250 mg/m\^2 IV q4w after Myozyme infusion for 6 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme® (alglucosidase alfa)
Description: Myozyme®: IV infusion of 20 mg/kg qow; Rituximab: 375 mg/m\^2 IV weekly beginning the day after Myozyme infusion for 4 weeks (an optional additional 2nd cycle could be administered at the discretion of the investigator); Methotrexate: 15 mg/m\^2 subcutaneous qow on the day after Myozyme infusion for 6 months.
Study: NCT03838614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmical auditory stimulation gait training (RAS)
Description: The RAS group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive RAS-treadmill training repeatedly within each 60-minute session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle power training (MPT)
Description: The MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive muscle power training repeatedly within each 60-minute session.

Intervention type: OTHER
Group type: OTHER
Intervention: Controls
Description: Participants in the control group will receive no intervention during the study period, but continue with their normal daily activities and usual medical care. They will receive the same training as the RAS-MPT group after the study.
Study: NCT02869126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)
Description: * During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient~* Stress conventional acquisition with D.SPECT camera 20 min after injection~* 60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)~* double isotope acquisition 5 min after thallium-201 injection~* injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection~* rest conventional acquisition 20 min later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Sestamibi
Description: First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thallium-201
Description: Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy
Study: NCT00565396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril and Losartan
Description: Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril and Losartan
Description: Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril and Losartan
Description: Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril and Losartan
Description: Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
Study: NCT01127633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: 400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
Study: NCT04116177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Stimulation using VerciseTM system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Stimulation using VerciseTM system
Study: NCT03917875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback intervention
Description: The novel integrated PFI will be developed and modeled from past PFIs targeting hazardous drinking. Participants will view feedback on the computer screen. The computer program/algorithm will determine the proper normative feedback to participants.
Study: NCT01568281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole ODF
Description: Each volunteer will receive a single dose of Anastrozole ODF with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimidex tablet
Description: Each volunteer will receive a single dose of Arimidex tablet with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole ODF
Description: Each volunteer will receive a single dose of Anastrozole ODF without water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimidex tablet
Description: Each volunteer will receive a single dose of Arimidex tablet with water
Study: NCT02026947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Benzoate
Description: 0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02704624

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
Study: NCT01794624

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy for Catastrophizing
Description: Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Therapy for Sleep Continuity Disturbance
Description: Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
Study: NCT03533699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: oral tablets with no active drug
Study: NCT02078050

Intervention type: OTHER
Group type: OTHER
Intervention: Phrenic nerves magnetic stimulations
Study: NCT02695017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iso inertial

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional machine